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OBJECTIVES: As pharmaceutical pipelines begin to churn out specialty products at a 
higher rate than traditional therapies, payers are experiencing double-digit growth 
in costs for biologics and other high-cost specialty drugs. Such agents are expected 
to consume half of the drug spend by 2018. Focusing on rheumatoid arthritis (RA), 
this study explored current uptake of biologics, and examined evolving payer pre-
scribing controls. METHODS: A total of 40 managed care organization (MCO) phar-
macy and medical directors, and 103 rheumatologists who prescribe biologics for 
RA were surveyed regarding prescribing and reimbursement. RESULTS: Surveyed 
rheumatologists reported that 59% of their drug-treated RA patients currently 
receive a biologic, with extensive use of Enbrel and Humira, especially, as first-line 
therapy. MCO tier coverage currently favors such TNF-α inhibitors, but surveyed 
payers indicated that, in one year’s time, newer biologics and non-TNF-α inhibitors 
that have previously been formulary-excluded will move to coverage tiers. More than 
80% of surveyed rheumatologists encounter strong-to-moderate payer control of RA 
biologics prescribing, with reports of increasing control and consequent decreased 
prescribing of specific agents. A large majority of payers confirmed using at least 
some form of restrictions, mostly prior authorization, and also step therapy and 
quantity limits. Higher copays for biologics versus other drugs are also encountered, 
and about half of payers reported a specialty pharmacy is commonly used to acquire 
biologic for RA. More than one-third of payers also reported that their contracting 
arrangements with drugmakers include rebating and price protection for RA biolog-
ics. CONCLUSIONS: As the biologics/specialty drug market for RA grows, increased 
prescribing controls by MCOs are likely. Furthermore, as competition increases, so 
will the demand for more extensive data and greater discounts/rebates to justify 
preferred coverage. Achieving preferred coverage is vital to avoid losing patient 
share to competitors achieving more favorable reimbursement terms.
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OBJECTIVES: As EU5 healthcare budgets tighten and cost-containment strategies 
become ever-more convoluted, the threat of biosimilars looms large for the rheu-
matoid arthritis (RA) biologic brands. With the first biosimilars for RA set to pen-
etrate these markets in 2015, this study explored their likely uptake as payers and 
prescribers balance clinical need with limited funds. METHODS: In September/
October 2014, 253 rheumatologists across the EU5 were surveyed regarding their 
views on biosimilars for RA, and on current and expected biologics prescribing 
patterns. In addition, 15 payers who influence reimbursement at national/regional 
level were interviewed. RESULTS: At least three-quarters of surveyed rheumatolo-
gists in each country (> 90% in Germany and Italy) plan to prescribe biosimilars of 
infliximab, etanercept, and rituximab within two years of launch, more frequently 
to new biologics patients than existing brand patients. Overall, however, in 2017, 
respondents expect less than half of their RA patients, on average, receiving any of 
these molecules to be on a biosimilar version. Interviewed payers in France, Italy, 
Spain, and the UK will encourage but not mandate biosimilar prescribing, largely 
due to anticipated modest discounts and corresponding price cuts to the brands. In 
Germany, however, payers believe that biosimilar prescribing targets and financial 
penalties for physicians who do not adhere will induce hefty discounts on bio-
similars as robust uptake will compensate. CONCLUSIONS: EU5 rheumatologists 
expect to prescribe biosimilars for RA; however, brand dominance is likely through 
2017 at least, due partly to modest discounts on the biosimilars resulting in lack of 
incentive for payers to promote their prescribing. Both prescribers and payers are 
also likely somewhat wary given the dearth of long-term RA biosimilar safety data. 
Over time, however, increasing confidence in biosimilars is probable, as are more 
aggressive payer policies encouraging prescribing across the EU5, especially as a 
favorable price-uptake ratio looks certain in Germany.
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OBJECTIVES: To identify factors associated with disease modifying antirheu-
matic drugs (DMARDs) receipt among Medicare beneficiaries enrolled in Medicare 
Advantage (MA) plans. METHODS: This study used a large nationally representa-
tive administrative claims data, supplemented by new sources of socioeconomic 
and community resource data (i.e., market source (at zip+4 levels) and area health 
resource files) in addition to CMS published contract information and Monthly 
Membership Report. The sample consisted of MA members (≥ 18 years) who were 
diagnosed with rheumatoid arthritis (RA) during 2013. The generalized linear mixed 
model was used to determine factors associated with DMARD receipt. RESULTS: A 
total of 12,835 RA patients were identified, of which 9,850 (76.74%) received DMARD. 
Factors associated with less likelihood of receiving DMARD were male gender (OR: 
0.72), increasing age (80-84 years, OR: 0.67; ≥ 85 years, OR: 0.45; vs. 18-54 years), more 
comorbidities (Charlson Comorbidity Index, OR: 0.96; HCC Risk Score, OR: 0.89), 
living in South Atlantic region compared to Mid-Atlantic (OR: 0.76), and percent 
households with 1st Individual who completed college (1-15% vs. 0%, OR: 0.82). 
Factors associated with more likelihood of DMARD receipt were Hispanic compared 
to White (OR: 1.38), use of glucocorticoids (OR: 2.22), living in New England region 
compared to Mid-Atlantic (OR: 1.82), median household income ($50,000-$74,999, 
OR: 1.31; $75,000 - $99,999, OR: 1.34; $100,000+, OR: 1.42; vs. $0-$15,000), end-stage 
renal disease (OR: 2.77), enrolled in employer group waiver plan (OR: 1.40), MA plans 
market penetration rate in service area (3-4%, OR: 1.26; 5-8%, OR: 1.45; 9-100%, OR: 
1.60; vs. 0-2%). CONCLUSIONS: The probability of receiving DMARD is correlated 
with sociodemographic, clinical, health plan and community characteristics. This 
study provides new evidence that can be used to identify subgroups of members to 
the follow-ups (a lot better/worse, a little better/worse, stayed the same). We estimated 
MIDs using the mean change in PROMIS scores for people who rated their change 
‘a little better’ or ‘a little worse.’ RESULTS: At 6 months, 41 patients reported their 
fatigue was a little better compared to baseline (mean change [SD]: -2.6 [4.8]), 119 a 
little worse (1.7 [5.6]). Pain was a little better for 60 patients (-1.9 [6.1]) and a little worse 
for 126 (0.6 [5.7]). At 12 months, fatigue was a little better compared to 6 months prior 
for 31 patients (-1.3 [6.5]) and a little worse for 133 (0.9 [5.6]). Pain was a little better 
for 53 patients (-1.8 [5.7]) and a little worse for 122 (1.5 [5.0]). Thus, the MID range 
was 1-2 points for both Fatigue and Pain Interference. Correlations between change 
scores and retrospective ratings were low (0.13-0.29), indicating that these analy-
ses may underestimate the MID. CONCLUSIONS: The MID for PROMIS Fatigue and 
PROMIS Pain Interference, estimated from this cohort of RA patients, is roughly 
2 points and corresponds to a small effect size. This is consistent with earlier 
work in this cohort demonstrating an MID of 2 points for PROMIS Physical Functioning.
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OBJECTIVES: We sought to identify whether region-specific (American Shoulder and 
Elbow Surgeon (ASES) and Disabilities of the Arm, Shoulder, and Hand (DASH)) or 
generic (EuroQOL 5D (EQ-5D) and Veterans Rand 6D (VR-6D)) patient-reported out-
comes instruments perform best in an orthopedics population with upper extremity 
morbidity (hand/wrist, elbow, or shoulder). METHODS: New patients presenting to our 
institution with complaints of upper extremity morbidity completed the ASES, DASH, 
EQ5D, and the Veterans Rand-12 (from which the VR-6D is derived). We oversampled 
patients at the initial visit to ensure adequate sample size for the six-month follow-
up. Based on standard of care, patients received conservative (e.g., casting), opera-
tive, or no treatment. Six-months after the initial appointment, patient-outcomes 
were reassessed. Performance of the instruments was examined, and compared over 
time, body parts, and treatment modality. RESULTS: A total of 294 patients provided 
responses at the first visit and six-months later. Of these patients, 21.4% reported 
to our institution for elbow morbidity, 40.5% for shoulder morbidity, and 38.1% for 
hand/wrist morbidity. The mean age of respondents was 56.5 years (hand/wrist: 57.3 
years, elbow: 52.2 years, shoulder: 57.9 years; p< 0.01). Mean initial scores were deter-
mined for the ASES: 60.9/100; DASH: 26.6/100 (reverse scored), EQ5D: 0.79/1, and VR6D: 
0.70/1. Significant differences in the initial and six-month scores were found for all 
instruments. Initial scores were poorer in the operative group for the VR6D, but the 
difference was not significant. Significant improvements were detected using the 
ASES and EQ5D, but not in the DASH or VR6D. Ceiling effects were noted for the DASH 
and EQ5D. The ASES and VR6D scores were normally distributed. CONCLUSIONS: 
We determined that a region-specific instrument, the ASES, had the most desirable 
psychometric properties in our patient population. To expand our findings, we are 
currently developing mapping algorithms between the generic preference-based and 
disease-specific measures to estimate health utilities.
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OBJECTIVES: Hip fractures are common in older people and incur substantial pain 
and suffering, disability, increased risk of death and high costs. The burden of hip 
fractures is expected to grow considerably during next years due to population 
aging. We aimed to describe the health-related quality of life (HRQoL) and the 
determinants in patients sustaining a hip fracture in Mexico. METHODS: Data 
from Mexican patients enrolled in the International Costs and Utilities Related to 
Osteoporotic Fractures Study (ICUROS) was gathered. Patients had to be diagnosed 
with a low-energy-induced hip fracture and to be at least 50 years old. HRQoL was 
prospectively collected in three phases over 12 months after fracture using the 
EQ-5D instrument. The UK preference weights were used to determine health util-
ity at different times. The accumulated HRQoL loss in the first year after fracture 
was calculated using the trapezoid method. Multivariate regression analysis was 
conducted to identify determinants of HRQoL reductions. RESULTS: 200 patients 
were evaluated. Mean (±SD) age was 77.4 ±9.9 years and 80% were women. A 15.5% 
of the sample reported a prior fracture in last 5 years; 54% had a job before fracture 
and 78% were classified into the low level of income category. Mean (95%CI) util-
ity value before fracture was 0.64 (0.59—0.68). Utility dropped to 0.01 (0.01—0.02) 
immediately after fracture and then improved to 0.46 (0.42—0.50) and 0.59 (0.55—
0.63) at month 4 and 12 post-fracture, respectively. Accumulated utility loss over 
the first year was 0.35 (0.31—0.39). HRQoL before hip fracture and age at fracture 
were the two most relevant characteristics associated with the accumulated utility 
loss. CONCLUSIONS: Hip fractures impair HRQoL in a significant way leading to 
utility values close to death shortly after fracture. Mean utility value elicited after 
one year follow-up was lower than before sustaining the fracture.
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